BrainCheck vs Neurotrack
Two population oriented cognitive screens that both keep the AI light, split by depth of evidence against breadth of distribution. BrainCheck carries the stronger record: published validation with sensitivity and specificity figures reported honestly, the clearest reimbursement guidance in the category naming actual CPT codes, and a named Class II regulated component. Neurotrack is built for reach rather than depth: cloud based on any device, sized to drop into a Medicare Annual Wellness Visit, integrating with all major EHRs in weeks, with named health system customers and the only published SOC 2 attestation of the four. Two honest cautions on Neurotrack: it is FDA registered rather than cleared, and much of its long publication record predates the current product after it removed its original eye tracking technology. If your failure mode is validated accuracy and a billable path, start with BrainCheck. If your failure mode is screening a whole population inside existing workflows, start with Neurotrack, understanding registration is not clearance.
- The stronger published validation: a 99 participant study reporting at least 88 percent sensitivity and specificity for dementia, an r=0.77 MoCA correlation, and a 529 participant multi site study, with the weak numbers reported alongside the good ones, graded A on clinical evidence where Neurotrack grades B.
- The reimbursement path is published: specific CPT codes, time based minimums, and telehealth eligibility in an annually updated guide, graded A on commercial transparency where Neurotrack publishes no code level guidance and grades C.
- Scope is drawn clearly and the regulated component is named: BrainCheck Assess is a Class II device stated as the single FDA regulated component, and the product is prominently not a stand alone diagnostic, graded A on autonomy.
- Population scale deployment is the design: cloud based, runs on any device with no specialised hardware, sized to fit inside a Medicare Annual Wellness Visit, graded A on both deployment and setting coverage where BrainCheck grades B.
- The broadest distribution and interoperability in the category: integrates with all major EHRs deploying in weeks, feeding Annual Wellness Visit compliance and RADV documentation, graded A on interoperability where BrainCheck names two EHRs and grades B.
- The only published security attestation among the four: SOC 2 and HIPAA stated directly on the product, graded B on security certifications where BrainCheck has none located.
Side-by-Side
| Axis | B BrainCheck |
N Neurotrack |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Both sit at the low AI end of this category, graded C on AI centrality: both deliver standardised digital tests with automated scoring rather than a model deriving novel signal. The difference is evidence against distribution. BrainCheck's evidence is stronger and current, graded A; Neurotrack grades B because a substantial share of its 25 paper record derives from the eye tracking research lineage the company has since removed from its clinician products, so the published evidence and the shipping product are not fully aligned, and sensitivity figures for the current three minute test were not located. On regulatory status BrainCheck is a Class II device graded B, while Neurotrack is FDA registered rather than cleared, a materially weaker position it describes accurately. Neurotrack's countervailing strengths are real: the widest distribution, the best interoperability, and the only SOC 2 disclosure in the category. Neither publishes pricing.